Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence

Lyu, Su Ir; Fretter, Caroline; Simon, Adrian Georg; Spielmann, Sarah-Michele; Damanakis, Alexander I.; Zhao, Yue; Bruns, Christiane J.; Schmidt, Thomas; Popp, Felix C.; Waldschmidt, Dirk; Quaas, Alexander; Knipper, Karl

doi:10.1016/j.tranon.2024.102044

Translational Oncology

2024

DOI: 10.1016/j.tranon.2024.102044

|View full text |Cite

Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence

Su Ir Lyu,

Caroline Fretter,

Adrian Georg Simon

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases

Du,

Xie,

et al. 2024

JHC

View full text Add to dashboard Cite

Hepatobiliary and pancreatic diseases are becoming increasingly common worldwide and associated cancers are prone to recurrence and metastasis. For a more accurate treatment, new therapeutic strategies are urgently needed. The claudins (CLDN) family comprises a class of membrane proteins that are the main components of tight junctions, and are essential for forming intercellular barriers and maintaining cellular polarity. In mammals, the claudin family contains at least 27 transmembrane proteins and plays a major role in mediating cell adhesion and paracellular permeability. Multiple claudin proteins are altered in various cancers, including gastric cancer (GC), esophageal cancer (EC), hepatocellular carcinoma (HCC), pancreatic cancer (PC), colorectal cancer (CRC) and breast cancer (BC). An increasing number of studies have shown that claudins are closely associated with the occurrence and development of hepatobiliary and pancreatic diseases. Interestingly, claudin proteins exhibit different effects on cancer progression in different tumor tissues, including tumor suppression and promotion. In addition, various claudin proteins are currently being studied as potential diagnostic and therapeutic targets, including claudin-3, claudin-4, claudin-18.2, etc. In this article, the functional phenotype, molecular mechanism, and targeted application of the claudin family in hepatobiliary and pancreatic diseases are reviewed, with an emphasis on claudin-1, claudin-4, claudin-7 and claudin-18.2, and the current situation and future prospects are proposed.

show abstract

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases

Du,

Xie,

et al. 2024

JHC

View full text Add to dashboard Cite

show abstract

Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)

Katoh,

Katoh

2024

Int J Mol Med

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence

Cited by 2 publications

References 29 publications

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases

Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)

Contact Info

Product

Resources

About